OpenAI acquires biotech startup Orchestra Bio to push into drug development

OpenAI is buying its way into one of the slowest industries on Earth. On October 20, 2026, the company announced it has acquired Orchestra Bio, a startup that uses AI to streamline how biopharma teams develop drugs. Moving a drug from discovery to market in the US can take anywhere from 10 to 15 years. What OpenAI is actually buying Orchestra Bio built a platform that lets humans and AI agents jointly manage drug programs. The company describes its product as an “agentic operating layer” that spans multiple stages of drug development. It is software that sits on top of a drug program and coordinates work across phases, with AI agents handling tasks alongside human scientists. OpenAI plans to combine Orchestra’s platform with its existing Rosalind suite. Rosalind includes models built for biological and chemical reasoning, along with data analysis tools. Rosalind’s tools are expected to gain Orchestra’s capabilities, with the goal of shrinking drug development timelines. The companies also aspire to build specialized agents that link scientific findings to concrete next steps in the drug pipeline. A young startup with a focused pitch Orchestra Bio was founded around October 2022 by ...